Literature DB >> 27050597

Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion.

Simon Wilkins1, Andrew Haydon, Ian Porter, Karen Oliva, Margaret Staples, Peter Carne, Paul McMurrick, Stephen Bell.   

Abstract

BACKGROUND: Many studies have shown significantly improved outcomes (reduced local recurrence and improved overall survival) for patients achieving a complete pathological response from neoadjuvant chemoradiotherapy.
OBJECTIVE: This study aimed to document the complete pathological response rate and outcomes in patients receiving preoperative long-course chemoradiotherapy stratified for the extent of T3 mesorectal invasion measured on preoperative imaging.
DESIGN: This is a retrospective study of prospectively collected data, of patients with rectal cancer in the Cabrini Monash University Department of Surgery colorectal neoplasia database, incorporating data from Cabrini Hospital and The Alfred Hospital, identifying patients entered between January 2010 and June 2014. PATIENTS AND SETTINGS: One hundred eighteen patients with T3 rectal cancer met the selection criteria for the study; 26 achieved complete pathological response (22%). MAIN OUTCOME MEASURES: Outcomes in terms of complete pathological response and oncological outcomes such as disease-free and overall survival were analyzed.
RESULTS: Patients with complete pathological response had significantly less preoperative invasion than those with no complete pathological response (p < 0.001). Depth of invasion was the only variable associated with complete pathological response (p < 0.002), and the likelihood of complete pathological response decreased by 35% for every millimeter of invasion. Complete pathological response was associated with increased disease-free survival (p = 0.018) and a lower risk of cancer progression (p = 0.046). Depth of invasion was associated with an increased risk of death after surgery; HR increased by 1.07 (95% CI, 1.00-1.15) for each 1-mm increase in invasion. LIMITATIONS: This was a retrospective study with the usual limitations, although these were minimized through the use of a clinician-driven prospective database.
CONCLUSIONS: The smaller the degree of T3 invasion, the higher the chance of achieving complete pathological response (up to 35%), which is associated with improved disease-free and overall survival. A higher complete pathological response rate is observed in early T3 disease in comparison with more extensive T3 invasion.

Entities:  

Mesh:

Year:  2016        PMID: 27050597     DOI: 10.1097/DCR.0000000000000564

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

1.  Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system.

Authors:  Antonio Manenti; Luca Roncati; Massimiliano Salati; Emilio Simonini; Maurizio Zizzo; Alberto Farinetti
Journal:  J Gastrointest Oncol       Date:  2017-02

2.  Morphologic predictors of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chongda Zhang; Feng Ye; Yuan Liu; Han Ouyang; Xinming Zhao; Hongmei Zhang
Journal:  Oncotarget       Date:  2017-12-19

3.  Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer.

Authors:  C H A Lee; S Wilkins; K Oliva; M P Staples; P J McMurrick
Journal:  BJS Open       Date:  2018-08-08

4.  One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer.

Authors:  Xueqing Sheng; Shuai Li; Yangzi Zhang; Jianhao Geng; Hongzhi Wang; Xianggao Zhu; Jizhong Quan; Yongheng Li; Yong Cai; Weihu Wang
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

5.  T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.

Authors:  Ian P Hayes; Elasma Milanzi; Rachel M Pelly; Peter Gibbs; Jeanette C Reece
Journal:  J Surg Oncol       Date:  2022-05-30       Impact factor: 2.885

6.  Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study.

Authors:  Xue-Qing Sheng; Hong-Zhi Wang; Shuai Li; Yang-Zi Zhang; Jian-Hao Geng; Xiang-Gao Zhu; Ji-Zhong Quan; Yong-Heng Li; Yong Cai; Wei-Hu Wang
Journal:  World J Gastrointest Oncol       Date:  2022-09-15

Review 7.  The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Authors:  Fatima Domenica Elisa De Palma; Gaetano Luglio; Francesca Paola Tropeano; Gianluca Pagano; Maria D'Armiento; Guido Kroemer; Maria Chiara Maiuri; Giovanni Domenico De Palma
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.